NCT02421939 2025-12-04A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) MutationAstellas Pharma IncPhase 3 Completed371 enrolled 36 charts 2 FDA